Issued Patents All Time
Showing 1–25 of 146 patents
| Patent # | Title | Co-Inventors | Date |
|---|---|---|---|
| 12410259 | CD47 targeted therapies for the treatment of infectious disease | Kipp Andrew Weiskopf, Kim J. Hasenkrug, Cheryl A. Stoddart, Joseph M. McCune | 2025-09-09 |
| 12370243 | Non-genotoxic conditioning regimen for stem cell transplantation | Judith A. Shizuru, Akanksha Chhabra, Benson M. George | 2025-07-29 |
| 12318448 | Use of TLR agonist and anti-CD47 agent to enhance phagocytosis of cancer cells | Mingye Feng, Jens-Peter Volkmer | 2025-06-03 |
| 12274746 | Dosing parameters for CD47 targeting therapies to hematologic malignancies | Ravindra Majeti, Mark P. Chao, Jie Liu, Jens-Peter Volkmer | 2025-04-15 |
| 12258399 | Methods for achieving therapeutically effective doses of anti-CD47 agents | Stephen Willingham, Maureen Howard, Jie Liu, Ravindra Majeti, Susan Sweeney Prohaska +2 more | 2025-03-25 |
| 12258403 | Methods for treating myeloma by achieving therapeutically effective doses of anti-CD47 antibody | Stephen Willingham, Maureen Howard, Jie Liu, Ravindra Majeti, Susan Sweeney Prohaska +2 more | 2025-03-25 |
| 12233093 | Engraftment of stem cells with a combination of an agent that targets stem cells and modulation of immunoregulatory signaling | Judith A. Shizuru, Kipp Andrew Weiskopf, Aaron Michael Ring, Akanksha Chhabra, Peter Schnorr | 2025-02-25 |
| 12195532 | High affinity SIRP-alpha reagents and methods of using | Aaron Michael Ring, Kenan Christopher Garcia, Kipp Andrew Weiskopf, Aron Levin | 2025-01-14 |
| 12194093 | Dosing parameters for CD47 targeting therapies to hematologic malignancies | Ravindra Majeti, Mark P. Chao, Jie Liu, Jens-Peter Volkmer | 2025-01-14 |
| 12162939 | Methods for manipulating phagocytosis mediated by CD47 | Siddhartha Jaiswal, Ravindra Majeti, Mark P. Chao | 2024-12-10 |
| 12091456 | Targeting aneurysm disease by modulating phagocytosis pathways | Nicholas J. Leeper | 2024-09-17 |
| 12037402 | Treatment of cancer with dual targeting of CD47 and EGFR | Stephen Willingham, Doris Po Yi Ho, Piero D. Dalerba, Kelly Marie McKenna, Jens-Peter Volkmer | 2024-07-16 |
| 12030944 | Enhanced depletion of targeted cells with CD47 blockade and an immune costimulatory agonist | Peter Schnorr, Akanksha Chhabra, Judith A. Shizuru, Kipp Andrew Weiskopf | 2024-07-09 |
| 11965034 | Antifibrotic activity of CD47 blockade in the liver | Gerlinde Wernig | 2024-04-23 |
| 11905333 | Selective immunodepletion of endogenous stem cell niche for engraftment | Agnieszka Czechowicz, Deepta Bhattacharya, Daniel Kraft | 2024-02-20 |
| 11844336 | Method for producing chimeric animal | Hiromitsu Nakauchi, Hideki Masaki, Motoo WATANABE | 2023-12-19 |
| 11814419 | High affinity PD-1 agents and methods of use | Aaron Michael Ring, Andrew Kruse, Aashish Manglik, Roy Louis Maute, Melissa N. McCracken +1 more | 2023-11-14 |
| 11807684 | Humanized and chimeric monoclonal antibodies to CD47 | Jie Liu, Ravindra Majeti | 2023-11-07 |
| 11780931 | CD47 targeted therapies for the treatment of infectious disease | Kipp Andrew Weiskopf, Kim J. Hasenkrug, Cheryl A. Stoddart, Joseph M. McCune | 2023-10-10 |
| 11780918 | Markers of acute myeloid leukemia stem cells | Ravindra Majeti, Siddhartha Jaiswal, Mark P. Chao | 2023-10-10 |
| 11773165 | Markers of acute myeloid leukemia stem cells | Ravindra Majeti | 2023-10-03 |
| 11766454 | Use of TLR agonist and anti-CD47 agent to enhance phagocytosis of cancer cells | Mingye Feng, Jens-Peter Volkmer | 2023-09-26 |
| 11760800 | Markers of acute myeloid leukemia stem cells | Ravindra Majeti | 2023-09-19 |
| 11760810 | Modified immunoglobulin hinge regions to reduce hemagglutination | Jie Liu, Ravindra Majeti | 2023-09-19 |
| 11718675 | Disrupting FC receptor engagement on macrophages enhances efficacy of anti-SIRPalpha antibody therapy | Jie Liu, Aaron Michael Ring, Jens-Peter Volkmer | 2023-08-08 |